Skip to main content

Cullinan Management, Inc. (CGEM)

NASDAQ: CGEM · IEX Real-Time Price · USD
23.05 -0.62 (-2.62%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap1.03B
Revenue (ttm)18.94M
Net Income (ttm)n/a
Shares Out43.54M
EPS (ttm)-2.54
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume130,804
Open23.42
Previous Close23.67
Day's Range22.44 - 23.98
52-Week Range22.01 - 59.85
Betan/a
Analystsn/a
Price Target51.75 (+124.5%)
Est. Earnings DateNov 11, 2021

About CGEM

Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of s...

IndustryBiotechnology
IPO DateJan 8, 2021
Employees28
Stock ExchangeNASDAQ
Ticker SymbolCGEM
Full Company Profile

Financial Performance

Financial Statements

News

Cullinan Oncology to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced its participation in the following upcoming investor conferences:

2 weeks ago - GlobeNewsWire

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the 100mg dose cohort

1 month ago - GlobeNewsWire

Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data

Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.

3 months ago - Zacks Investment Research

Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific...

CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announ...

3 months ago - GlobeNewsWire

Why Cullinan Oncology Stock Is Skyrocketing Today

The company announced encouraging clinical data for its experimental lung cancer drug.

3 months ago - The Motley Fool

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl's CLN-081 in NSCLC EGFR Exon 20 Patients

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announ...

3 months ago - GlobeNewsWire

Cullinan Oncology Announces Management Transition

CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announc...

4 months ago - GlobeNewsWire

Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021

CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announc...

4 months ago - GlobeNewsWire

Cullinan Oncology Reports First Quarter 2021 Financial Results

Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations

4 months ago - GlobeNewsWire

Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that the company's Chief Financial Officer, Jeff Trigilio, will present at the up...

5 months ago - GlobeNewsWire

Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights

Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional INDs to be filed in 2021 for immuno-oncology assets Cullinan Florent...

5 months ago - GlobeNewsWire

Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology an...

6 months ago - GlobeNewsWire

Cullinan Management, Inc. Announces Business Update

February 22, 2021

7 months ago - GlobeNewsWire

Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchas...

CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-onc...

8 months ago - GlobeNewsWire

Cullinan Management Announces Pricing of Upsized Initial Public Offering (CORRECTION)

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Please note that the embedded hyperlinks in the press release below have been corrected from a release issued under the same headline earlier today.

8 months ago - GlobeNewsWire

Cullinan Management Announces Pricing of Upsized Initial Public Offering Nasdaq:CGEM

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline...

8 months ago - GlobeNewswire

Oncology biotech Cullinan Management increases deal size by 30% ahead of $195 million IPO

Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised the proposed deal size for its upcoming IPO on Wednesday.

8 months ago - NASDAQ

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China Nas...

- Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in...

8 months ago - GlobeNewswire

Cullinan Oncology Completes $131.2 Million Series C Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative...

9 months ago - Business Wire

Cullinan Management IPO Registration Document (S-1)

Cullinan Management, Inc. has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC